Shandong Suncadia Medicine Co., Ltd.

This study tests a new drug called HRS-7058 combined with other anti-tumor medicines in 100 adults with solid tumors. The goal is to find a safe dose and see if the combination can shrink tumors. Participants must be 18-75, in good general health, and have a life expectancy of at…

This study tests whether a new drug called HRS-1780 can slow down kidney function loss in people with chronic kidney disease. About 1,978 adults with moderate to severe kidney damage will receive either the drug or a placebo, on top of their usual care. The main goal is to see if…

This early-phase study tests a new oral drug, HRS-7058, in adults with advanced solid tumors that have a specific KRAS G12C mutation. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. About 233 participants will receive the drug, an…

This study tests a new drug combo (HRS-8080 plus dalpiciclib) in 146 women with a common type of advanced breast cancer that has spread or can't be removed. The goal is to see if it's safe and shrinks tumors. Participants must have tried at least one prior hormone therapy. This i…

This study tests a new drug called HRS-8080 against standard hormone therapy in people with intermediate or high risk early breast cancer who have already had at least 2 years of hormone treatment. The goal is to see if HRS-8080 can better prevent the cancer from coming back or s…

This study tests a new drug called HRS-7058 combined with other cancer drugs in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the combination is safe and can shrink tumors. About 300 adults aged 18 to 75 with good perfor…

This study checks the long-term safety of a drug called HRS-1893 in 300 people with hypertrophic cardiomyopathy, a condition where the heart muscle thickens. Participants must have taken HRS-1893 in a past study. Researchers will monitor side effects and heart function, like ejec…

This study tests several combinations of new and existing drugs in women with advanced breast cancer that cannot be surgically removed or has spread to other parts of the body. About 180 participants will receive different drug mixes to find the safest doses and see if the treatm…

This phase 3 trial tests whether a new drug (HRS-8080) combined with dalpiciclib works better than a standard drug (fulvestrant) combined with dalpiciclib for people with advanced breast cancer that no longer responds to hormone therapy. About 912 women aged 18-75 with locally ad…

This early-phase study tests a new drug called HRS-6208 in about 206 adults with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or…

This early-phase study tests a new drug called HRS-3802 in about 100 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants will receive the…

This study tests a new medicine called HRS-1301 for people with high cholesterol (dyslipidemia). About 189 adults will receive either the drug or a placebo for 12 weeks to see how well it lowers bad cholesterol and if it is safe. The goal is to find the best dose for future use.

This study tests a new medicine called HRS-1780 in 60 adults with primary aldosteronism, a condition where the adrenal glands make too much of a hormone that raises blood pressure. Participants will receive either the drug or a placebo to see if it safely lowers blood pressure be…

This phase 3 trial tests a new drug called HRS-8080 against standard treatments chosen by doctors for women with advanced breast cancer that has worsened after hormone therapy. About 240 women aged 18-75 will be randomly assigned to receive either HRS-8080 or another treatment. T…

This study tests a new medicine called HRS-1893 in 48 adults with a type of heart failure where the heart pumps normally but is too stiff. The goal is to see if the drug is safe and can improve heart function and daily life. Participants will receive either the drug or a placebo,…

This study tests an experimental tablet called HRS-7085 in 66 adults with moderate to severe ulcerative colitis, a chronic bowel disease. Participants are randomly assigned to receive either the drug or a placebo to see if it safely improves symptoms like diarrhea and rectal blee…

This study tests several new drug combinations in people with advanced breast cancer that cannot be removed by surgery or has spread. The goal is to find safe doses and see if the drugs shrink tumors. About 300 adults will take part. The study is currently recruiting.

This study tests a new drug called HRS-2129 to see if it can safely reduce nerve pain caused by diabetes. About 168 adults with diabetic nerve pain will receive either HRS-2129, a placebo (dummy pill), or an approved pain drug (pregabalin) for comparison. The main goal is to meas…

This study is testing a new medicine called HRS-2129 to see if it safely reduces pain after orthopedic surgery (like bone or joint procedures). About 195 adults having planned orthopedic surgery will receive the drug, and researchers will monitor side effects and pain levels over…

This study tests a new drug called HRS-2129 in 200 people with moderate to severe knee osteoarthritis pain. The goal is to see if different doses can reduce pain and improve knee function, while also checking safety. Participants must stop other pain treatments during the study, …

This study tests a new medicine called HRS-2129 to see if it can better control pain after abdominal surgery. About 360 adults having abdominal surgery will receive either HRS-2129 or a standard painkiller. The main goal is to measure how much pain relief patients feel during the…

This study tests a new drug called HRS-7535 in 225 adults with heart failure (a mild type) and obesity. Participants will receive either the drug or a placebo for 36 weeks. The main goal is to see if the drug helps with weight loss, which may ease heart failure symptoms.

This study tests whether two different versions of HRS-1893 tablets are processed the same way in the body. It involves 36 healthy adults aged 18 to 55. The goal is to measure drug levels in the blood, not to treat any disease.

This study looks at how a new cholesterol-lowering tablet, HRS-1301, behaves in people with mild, moderate, or severe kidney problems compared to those with healthy kidneys. About 36 adults aged 18 to 65 will take a single dose, and researchers will measure drug levels and safety…